Secuado (Asenapine) Patent Expiration, LOE Window & CMS Spending
Secuado (Asenapine) by Hisamitsu: FDA Orange Book LOE 2033-09-22, 3 AB generics, $9.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Hisamitsu |
| FDA Application & Pathway | N212268 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-09-22 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $9.2M |
| 2024 Medicare Part D Spend | $6.1M |
| 2024 Medicaid Spend | $3.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |